TAK-925

Phase 1Small molecule

Takeda

TAK-925 is one of 79 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obstructive Sleep ApneaActive, not recruiting

Idiopathic HypersomniaActive, not recruiting

NarcolepsyActive, not recruiting

Obstructive Sleep ApneaPhase 1

Active, not recruiting

Idiopathic HypersomniaPhase 1

Active, not recruiting

NarcolepsyPhase 1

Active, not recruiting

Competition

Competitive Landscape

149 competitors in Obstructive Sleep Apnea

#DrugCompanyPhaseTrials

Asmanex

Novartis

Phase 3

1 2

Farxiga

AstraZeneca

Phase 3

1 3

Mounjaro

Eli Lilly

Phase 3

1 4

Foundayo

Eli Lilly

Phase 3

1 5

MS Contin

Lunesta

3 7

MS Contin

HHikma Pharmaceuticals LLC

Phase 3

2 8

Ketalar

AAultman Health Foundation

Phase 3

2 9

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

1 10

Imovane

TTaisho Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Narcolepsy2 trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy

Completed· Takeda logo

Takeda·Phase 1·NCT03748979·57 enrolled

Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy

Completed· Takeda logo

Takeda·Phase 1·NCT03332784·58 enrolled

Idiopathic Hypersomnia1 trial

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

Completed· Takeda logo

Takeda·Phase 1·NCT04091438·28 enrolled

Adult1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

Completed· Takeda logo

Takeda·Phase 1·NCT03522506·20 enrolled

Obstructive Sleep Apnea1 trial

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

Completed· Takeda logo

Takeda·Phase 1·NCT04091425·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TAK-925. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-925 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-925. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Takeda

TAK-925

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Narcolepsy2 trials

Idiopathic Hypersomnia1 trial

Adult1 trial

Obstructive Sleep Apnea1 trial

References

Drug Info

Quick Facts

Related News